David Epstein, the Seagen CEO who helped sell the company to Pfizer in a blockbuster deal, is back to lead a new startup.

products which all lag behind the leaders in their particular cancer sub-types, but which Novartis will aim to revive, using its proven track record in oncology franchise management. Meanwhile GSK ...

Novartis NVS announced that the Committee for Medicinal Products for Human Use (“CHMP”) of the European Medicines Agency (EMA ...

TD Cowen analyst Steve Scala maintained a Hold rating on Novartis (NVS – Research Report) today. The company’s shares closed ...

Novartis is paying Chengdu Baiyu Pharmaceutical ... The biotech said its cancer research is focused on targeted radiotherapy and immuno-oncology. Baiyu began a pair of early-phase trials of ...

Novartis aims to enhance Pluvicto's market presence while exploring growth in multiple sclerosis and expanding its ...

Novartis raised its 2024 earnings guidance for the third time on Tuesday, buoyed by wider use of its prescription drugs, but ...

The pharmaceutical giant raised its full-year guidance for the third time this year after higher third-quarter profit and ...

One of the largest pharmaceutical companies in the world, Novartis AG, has posted strong quarterly results ... immunology, ...

Novartis AG ( (NVS) ) has realeased its Q3 earnings. Here is a breakdown of the information Novartis AG presented to its investors. Novartis AG ...

Novartis (NYSE:NVS – Get Free Report) is scheduled to be issuing its quarterly earnings data before the market opens on ...

LONDON — Novartis on Tuesday increased its earnings guidance for the third time this year, boosted by strong sales of its leading drugs. The company said it anticipates full-year operating ...